↓ Skip to main content

Dove Medical Press

Bevacizumab for glioblastoma

Overview of attention for article published in Therapeutics and Clinical Risk Management, December 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (83rd percentile)
  • High Attention Score compared to outputs of the same age and source (83rd percentile)

Mentioned by

twitter
4 X users
patent
2 patents

Citations

dimensions_citation
36 Dimensions

Readers on

mendeley
78 Mendeley
Title
Bevacizumab for glioblastoma
Published in
Therapeutics and Clinical Risk Management, December 2015
DOI 10.2147/tcrm.s58289
Pubmed ID
Authors

Yoshitaka Narita

Abstract

Individuals with glioblastoma are often characterized by older age, advanced neurologic manifestations at the primary stage, and unresectable tumors, and these factors are associated with poor treatment outcomes. Administration of bevacizumab (BV, Avastin(®)) promotes tumor regression and improves cerebral edema, and is expected to improve neurologic findings in many patients with malignant gliomas, including glioblastoma. Although the addition of BV to the conventional standard therapy (chemoradiotherapy with temozolomide) for newly diagnosed glioblastoma prolonged the progression-free survival time and the performance status of patients, it failed to extend overall survival time. However, more than 50% of glioblastoma patients show Karnofsky performance status ≤70 at initial presentation; therefore, BV should be used to improve or maintain their performance status as an initial treatment. Most of the adverse events of BV, except hypertension and proteinuria, occur as complications of glioblastoma, and explanation of the advantages and disadvantages of BV administration to patients is important. Herein, the efficacy, safety, and challenges of using BV for treating glioblastoma were reviewed.

X Demographics

X Demographics

The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 78 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Netherlands 1 1%
Turkey 1 1%
Unknown 76 97%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 15 19%
Student > Ph. D. Student 14 18%
Student > Master 10 13%
Researcher 7 9%
Other 6 8%
Other 13 17%
Unknown 13 17%
Readers by discipline Count As %
Medicine and Dentistry 21 27%
Agricultural and Biological Sciences 11 14%
Biochemistry, Genetics and Molecular Biology 7 9%
Immunology and Microbiology 4 5%
Nursing and Health Professions 3 4%
Other 17 22%
Unknown 15 19%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 October 2023.
All research outputs
#4,261,992
of 25,374,647 outputs
Outputs from Therapeutics and Clinical Risk Management
#206
of 1,323 outputs
Outputs of similar age
#65,484
of 395,421 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#7
of 43 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,323 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 395,421 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 83% of its contemporaries.
We're also able to compare this research output to 43 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 83% of its contemporaries.